<p>Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac introduction by administrative methods and Clustered Lot Quality Assurance Sampling (CLQAS) survey, Niamey and Tillabéri, Niger, December 2010.</p
BACKGROUND: A meningococcal group A conjugate vaccine, PsA-TT (also known as MenAfriVac), was develo...
Summary: Background: As of the end of 2021, twenty-four countries in the African meningitis belt ha...
Vaccination coverage for ≥2 doses of PCV10 among the <5 years old per year during the pre-interventi...
<p>Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the Men...
<p>MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by admini...
MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the A...
<p>Vaccination coverage per age group for seasonal influenza vaccination and first and second doses ...
In 2015, the World Health Organization substantially revised its guidance for vaccination coverage c...
Weighted vaccination coverage estimates for the democratic republic of the Congo demographic and hea...
Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meni...
For more than a century, epidemic meningococcal disease mainly caused by serogroup A Neisseria menin...
<p>Vaccination coverage by age in the areas targeted for vaccination in 2014.</p
Despite recent success towards controlling poliovirus transmission, Nigeria has struggled to achieve...
<p><sup>a</sup> Periods of MenC conjugate vaccine campaigns: February-December 2010 for <5 years old...
The countries of the African meningitis belt suffer from frequent epidemics due to meningococcal men...
BACKGROUND: A meningococcal group A conjugate vaccine, PsA-TT (also known as MenAfriVac), was develo...
Summary: Background: As of the end of 2021, twenty-four countries in the African meningitis belt ha...
Vaccination coverage for ≥2 doses of PCV10 among the <5 years old per year during the pre-interventi...
<p>Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the Men...
<p>MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by admini...
MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the A...
<p>Vaccination coverage per age group for seasonal influenza vaccination and first and second doses ...
In 2015, the World Health Organization substantially revised its guidance for vaccination coverage c...
Weighted vaccination coverage estimates for the democratic republic of the Congo demographic and hea...
Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meni...
For more than a century, epidemic meningococcal disease mainly caused by serogroup A Neisseria menin...
<p>Vaccination coverage by age in the areas targeted for vaccination in 2014.</p
Despite recent success towards controlling poliovirus transmission, Nigeria has struggled to achieve...
<p><sup>a</sup> Periods of MenC conjugate vaccine campaigns: February-December 2010 for <5 years old...
The countries of the African meningitis belt suffer from frequent epidemics due to meningococcal men...
BACKGROUND: A meningococcal group A conjugate vaccine, PsA-TT (also known as MenAfriVac), was develo...
Summary: Background: As of the end of 2021, twenty-four countries in the African meningitis belt ha...
Vaccination coverage for ≥2 doses of PCV10 among the <5 years old per year during the pre-interventi...